TABLE 4.
Summary of synthetic lethality among slt and slu mutations
| Mutation | Growth phenotype of double mutant containinga:
|
|||||
|---|---|---|---|---|---|---|
| slt11b | slt15c | slt16b | slt17c | slt21d | slt22b | |
| slt11b | NA | |||||
| slt15c | − | NA | ||||
| slt16b | + | + | NA | |||
| slt17c | − | − | + | NA | ||
| slt21d | + | + | + | +/− | NA | |
| slt22b | + | + | ND | + | + | NA |
| slu4c | − | NA | + | −* | + | ND |
| slu7c | − | −* | + | NA | +/− | ND |
| prp16c | − | −* | NA | −* | +/− | ND |
| prp2-1b | + | ND | ND | + | + | + |
a
slt15 is prp17-100, slt16 is smd3-1, slt17 is slu7-100, slu4 is prp17-2, and slt21 is prp8-21. Symbols: +, the double mutant is viable and without additive defect; −, the double mutant is lethal (i.e., it has synthetic lethality); +/−, the double mutant is viable but confers a severe growth defect (slow growth at 25°C, i.e., it has partial synthetic lethality); and *, see reference 14. NA, not applicable; ND, not determined.
b
Mutations block splicing prior to the first step.
c
Required for the second step.
d
Required for both steps.